Go Deep
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 15,817 | 39.1 | 18.41 | 0.01 | 2,464.40 |
GlaxoSmithKline Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 9,384,400,000.0 | 9,953,000,000.0 | 10,412,600,000.0 | 8,051,700,000.0 |
| Net Profit | 2,371,800,000.0 | 2,778,600,000.0 | 2,956,200,000.0 | 2,050,100,000.0 |
| EPS | 14.0 | 16.4 | 17.4 | 12.1 |
GlaxoSmithKline Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 38,075,535,000.0 | 37,260,347,000.0 | 34,417,708,000.0 | 32,263,787,000.0 | — |
| Net Profit | 10,359,824,000.0 | 9,275,829,000.0 | 5,899,610,000.0 | 6,106,868,000.0 | — |
| EPS | 61.1 | 54.8 | 34.8 | 36.0 | — |
GlaxoSmithKline Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 43,238,664,000.0 | 41,080,655,000.0 | 35,566,175,000.0 | 33,265,848,000.0 | — |
| Total Liabilities | 20,564,532,000.0 | 21,567,548,000.0 | 17,789,778,000.0 | 15,853,118,000.0 | — |
| Total Equity | 22,674,132,000.0 | 19,513,107,000.0 | 17,776,397,000.0 | 17,412,730,000.0 | — |
Owes vs Owns
GlaxoSmithKline Pharmaceuticals Limited owed ₹0.48 for every ₹1 it owned in Mar 2026, about the same as ₹0.48 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.48× | 0.53× | 0.50× | 0.48× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
GlaxoSmithKline Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 63.7%Receivables 6.3%Inventory 10.6%Fixed assets (tangible) 7.1%Other assets 12.1%
How it's funded — Mar 2026
Payables 13.2%Other liabilities 33.6%Shareholders' equity 52.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,756.3 | 2,498.1 | 1,856.8 | 1,654.1 |
| Receivables | 273.1 | 292.5 | 222.1 | 192.4 |
| Inventory | 457.6 | 481.7 | 525.0 | 460.0 |
| Fixed assets (tangible) | 306.4 | 283.9 | 310.7 | 315.1 |
| Intangible assets | 6.6 | 13.3 | 23.6 | 34.1 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 523.8 | 538.5 | 618.4 | 670.9 |
| Liabilities & equity | ||||
| Short-term debt | 16.0 | 7.5 | 12.2 | 12.1 |
| Long-term debt | 17.3 | 2.5 | 6.5 | 3.5 |
| Payables | 570.2 | 708.2 | 625.4 | 427.8 |
| Other liabilities | 1,453.0 | 1,438.6 | 1,134.9 | 1,142.0 |
| Shareholders' equity | 2,267.4 | 1,951.3 | 1,777.6 | 1,741.3 |
| Net tangible assets | 2,260.9 | 1,938.0 | 1,754.1 | 1,707.2 |
GlaxoSmithKline Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 9,032,996,000.0 | 12,898,974,000.0 | 5,820,155,000.0 | 4,842,254,000.0 | — |
| Investing Activities | 3,969,817,000.0 | -458,007,000.0 | 87,117,000.0 | 8,078,514,000.0 | — |
| Financing Activities | -7,370,784,000.0 | -7,694,202,000.0 | -5,614,969,000.0 | -15,433,230,000.0 | — |